Autoimmunity and Age-Related Macular Degeneration

自身免疫和年龄相关性黄斑变性

基本信息

项目摘要

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a highly prevalent, multifactorial, polygenic complex disease. It is now widely accepted that inflammation and the immune system play a direct role in the pathogenesis of AMD. As inflammation builds up in aging and, much more so, in AMD, we hypothesize that a vicious cycle is set in motion that exposes macular tissues to an increasing amount of inflammatory and immune-mediated damage. We propose that this mechanism is critical to AMD development and progression. We have strong evidence that patients with early and advanced AMD express auto-antibodies (auto-Abs) against macular human tissue antigens significantly more commonly and more intensely than elderly controls. However, having shown this does not prove that the auto-Abs have a direct role in contributing to disease development and/or progression. To understand the role of auto-Abs in AMD, it is essential to discover the identity of their targets, and provide prof of a causal link between disease and presence of auto-Abs. To tackle these critically important questions, we propose the following series of Aims: 1) To discover the identity of all statisticall significant macular antigens identified in our preliminary investigations and test the hypothesis that wild-type (WT) mice immunized against these antigens develop auto-Abs towards them and changes consistent with an AMD phenotype. 2) To test the hypothesis that auto-Abs that develop in an early-onset murine model of AMD can be used to accelerate disease appearance and increase its severity in a late-onset model via adoptive transfer of serum IgG. 3) To test the hypothesis that similar autoimmune reactivity patterns occur not only across species but also across animal models of AMD, and to establish a relationship between time course of auto-Ab development and time of onset of phenotypes. These studies will allow us to discover targets of autoreactivity in AMD, investigate commonalities (and differences) across species and models, test the causality of the autoimmune hypothesis in AMD, define an "autoreactivity sequence", identify early disease markers and progression risk markers, and develop a much more refined pathogenic framework for the role of autoimmunity in AMD. We predict that these studies will ultimately pave the way toward using the existing AMD models and those that we plan to induce to investigate and develop new treatments for the manifestations of AMD, and that it will be possible to translate these treatments back to bedside in human clinical trials. PUBLIC HEALTH RELEVANCE: The role of inflammation has recently emerged as a key pathogenic factor in age-related macular degeneration (AMD). We have documented that AMD patients have autoantibodies (auto-Abs) against macular tissue antigens significantly more commonly and more intensely than controls. We now propose to: (1) identify the antigens recognized by these auto-Abs with immunoprecipitation and mass spectrometry experiments; (2) test the hypothesis that these auto-Abs are pathogenic and that a) by immunizing mice against the antigens that they recognize mice will develop AMD-like fundus lesions and b) that passive (adoptive) transfer of the auto-Abs developed by these mice to naive mice will lead to disease development also in these mice; (3) test the hypothesis that, like human beings, existing mouse models of AMD also develop autoreactivities against ocular tissue antigens; (4) to test the hypothesis that late-onset mouse models of AMD can have their disease appearance be sped up or its severity made worse by passive transfer of auto-Abs from other models in which disease also is present; and (5) to investigate mouse models of AMD prospectively to characterize the sequence of events leading up to auto-Ab formation and development of fundus lesions. This series of studies will allow us to define the role that autoimmunity has in AMD and, ultimately, to pave the way toward using the existing AMD models and those that we plan to induce to explore treatments of the manifestations of AMD.
描述(由申请人提供):视网膜相关性黄斑变性(AMD)是一种高度流行的多因素多基因复杂疾病。目前普遍认为炎症和免疫系统在AMD的发病机制中起直接作用。随着炎症在衰老中的积累,在AMD中更是如此,我们假设一个恶性循环正在启动,使黄斑组织暴露于越来越多的炎症和免疫介导的损伤。我们认为这种机制对AMD的发展和进展至关重要。我们有强有力的证据表明,早期和晚期AMD患者比老年对照组更普遍和更强烈地表达针对黄斑人类组织抗原的自身抗体(自身抗体)。然而,这并不能证明自身抗体在促进疾病发展和/或进展中具有直接作用。为了了解自身抗体在AMD中的作用,必须发现其靶点的身份,并提供疾病和自身抗体存在之间的因果关系。为了解决这些至关重要的问题,我们提出了以下一系列的目的:1)发现在我们的初步研究中鉴定的所有具有免疫学意义的黄斑抗原的身份,并测试针对这些抗原免疫的野生型(WT)小鼠产生针对它们的自身抗体和与AMD表型一致的变化的假设。2)为了验证以下假设:在早发性AMD小鼠模型中产生的自身抗体可通过血清IgG的过继转移来加速迟发性模型中疾病的出现并增加其严重程度。3)为了检验不仅在物种之间而且在AMD动物模型之间发生相似的自身免疫反应模式的假设,并建立自身抗体发展的时间过程与表型发作时间之间的关系。这些研究将使我们能够发现AMD中自身反应性的靶点,研究跨物种和模型的共性(和差异),测试AMD中自身免疫假说的因果关系,定义“自身反应性序列”,鉴定早期疾病标志物和进展风险标志物,并为自身免疫在AMD中的作用开发更精细的致病框架。我们预测,这些研究最终将为使用现有的AMD模型和我们计划诱导的模型来研究和开发针对AMD表现的新治疗方法铺平道路,并且将有可能将这些治疗方法转化回人类临床试验的床边。 公共卫生相关性:炎症的作用最近已成为年龄相关性黄斑变性(AMD)的关键致病因素。我们已经证明,AMD患者具有针对黄斑组织抗原的自身抗体(自身抗体),其比对照组显著更常见且更强烈。我们现建议:(1)通过免疫沉淀和质谱实验鉴定这些自身抗体识别的抗原;(2)检验以下假设:这些自身抗体是致病性的,并且a)通过针对它们识别的抗原免疫小鼠,小鼠将发展AMD样眼底病变,以及B)被动免疫小鼠,将由这些小鼠产生的自身抗体(过继)转移至未处理小鼠也将导致这些小鼠中的疾病发展;(3)检验如下假设:与人类一样,现有的AMD小鼠模型也产生针对眼组织抗原的自身反应性;(4)验证迟发性AMD小鼠模型可通过自身免疫细胞的被动转移加速其疾病外观或使其严重程度恶化的假设。来自其中也存在疾病的其他模型的Ab;和(5)前瞻性地研究AMD的小鼠模型以表征导致自体Ab形成和眼底病变发展的事件序列。这一系列研究将使我们能够定义自身免疫在AMD中的作用,并最终为使用现有的AMD模型和我们计划诱导的模型探索AMD表现的治疗方法铺平道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALESSANDRO IANNACCONE其他文献

ALESSANDRO IANNACCONE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALESSANDRO IANNACCONE', 18)}}的其他基金

Autoimmunity and Age-Related Macular Degeneration
自身免疫和年龄相关性黄斑变性
  • 批准号:
    8708878
  • 财政年份:
    2012
  • 资助金额:
    $ 37.5万
  • 项目类别:
Autoimmunity and Age-Related Macular Degeneration
自身免疫和年龄相关性黄斑变性
  • 批准号:
    8530237
  • 财政年份:
    2012
  • 资助金额:
    $ 37.5万
  • 项目类别:
Auto-Antibodies as Serum Biomarkers for Age-Related Macular Degeneration
自身抗体作为年龄相关性黄斑变性的血清生物标志物
  • 批准号:
    7895584
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
Auto-Antibodies as Serum Biomarkers for Age-Related Macular Degeneration
自身抗体作为年龄相关性黄斑变性的血清生物标志物
  • 批准号:
    7471805
  • 财政年份:
    2009
  • 资助金额:
    $ 37.5万
  • 项目类别:
CLINICAL EPIDEMIOLOGY OF RETINAL DEGENERATIONS
视网膜变性的临床流行病学
  • 批准号:
    6889865
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
CLINICAL EPIDEMIOLOGY OF RETINAL DEGENERATIONS
视网膜变性的临床流行病学
  • 批准号:
    6738998
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
CLINICAL EPIDEMIOLOGY OF RETINAL DEGENERATIONS
视网膜变性的临床流行病学
  • 批准号:
    6331691
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
CLINICAL EPIDEMIOLOGY OF RETINAL DEGENERATIONS
视网膜变性的临床流行病学
  • 批准号:
    6518263
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:
CLINICAL EPIDEMIOLOGY OF RETINAL DEGENERATIONS
视网膜变性的临床流行病学
  • 批准号:
    6635541
  • 财政年份:
    2001
  • 资助金额:
    $ 37.5万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 37.5万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 37.5万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 37.5万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 37.5万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 37.5万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 37.5万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 37.5万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 37.5万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 37.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了